Oral drugs stimulating endogenous insulin production (insulin secretagogues) may have detrimental effects on breast cancer outcomes. The data presented shows the relationship between pre-existing insulin secretagogues use, adipokine profiles at the time of breast cancer (BC) diagnosis and subsequent cancer outcomes in women diagnosed with BC and type 2 diabetes mellitus (T2DM). The Pearson correlation analysis evaluating the relationship between adipokines stratified by T2DM pharmacotherapy and controls is also provided. This information is the extension of the data presented and discussed in "Insulin use, adipokine profiles and breast cancer prognosis" (Wintrob et al., in press) [1] .
Specifications
Tumor registry query was followed by vital status ascertainment, and medical records review Luminex s -or enzyme-linked immunosorbent assay-based quantitation of adipokines (adiponectin, leptin, C-reactive protein, interleukine-6, interleukine-1β, interleukine-1Ra, tumor necrosis factor-α, and C-peptide) from plasma samples was conducted. 
Data accessibility
The data is with this article
Value of the data
Presented data shows the relationship between pre-existing insulin secretagogues use, adipokine production at the time of cancer diagnosis and breast cancer outcomes.
This data serves as a benchmark for future investigations targeting pharmacotherapy-induced adipokine modulation in breast cancer.
The data described here can assist study design of further biomarker evaluation in relationship with the safety and effectiveness of diabetes pharmacotherapy.
Data
Reported data represents the observed association between insulin secretagogues' utilization and the adipokine profiles at the time of breast cancer diagnosis in women with diabetes mellitus (Table 1) . Data in Table 2 includes the observed correlations between adipokines stratified by type 2 diabetes mellitus pharmacotherapy and controls.
Experimental design, materials and methods
Evaluation of adipokine profile association with insulin secretagogue use and BC outcomes was carried out under two protocols approved by both Roswell Park Cancer Institute (EDR154409 and NHR009010) and the State University of New York at Buffalo (PHP0840409E). Demographic and clinical patient information was linked with cancer outcomes and adipokine profiles of corresponding plasma specimen harvested at BC diagnosis and banked in the Roswell Park Cancer Institute Data Bank and Bio-Repository. C-reactive protein (CRP), interleukine-6 (IL-6), interleukine-1β (IL-1β), interleukine-1Ra (IL-1Ra), tumor necrosis factor-α (TNF-α). n Overall survival (OS)-and disease-free survival (DFS)-optimized biomarker ranges associated with poorer outcomes are represented in bold. BLQ ¼ below limit of quantitation.
MVP¼ p-value of the multivariate adjusted analysis. Significant correlations are displayed in bolded text. The differences that are only significant in either adjusted or unadjusted correlations are further denoted by an outline. C-reactive protein (CRP), interleukine-6 (IL-6), interleukine-1β (IL-1β), interleukine-1Ra (IL-1Ra), tumor necrosis factor-α (TNF-α), confidence interval (CI).
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Study population
As described in the original research article by Wintrob et al. [1] , all incident breast cancer cases diagnosed at Roswell Park Cancer Institute (01/01/2003-12/31/2009) were considered for inclusion (n ¼2194). Medical and pharmacotherapy history were used to determine the baseline presence of diabetes.
Inclusion and exclusion criteria
Inclusion criteria were as follows: minimum 18 years of age at diagnosis, presence of pre-existing diabetes at breast cancer diagnosis, and having available banked treatment-naïve plasma specimens in the Institute's Data Bank and Bio-Repository. That is, the blood had to be collected prior to the initiation of any cancer-related therapy (surgery, radiation or pharmacotherapy).
Subjects were excluded if they were male, had prior cancer history or unclear date of diagnosis, incomplete clinical records, type 1 or unclear diabetes status. For a specific breakdown of excluded subjects, please see the original research article by Wintrob et al. [1] .
A total of 97 female subjects with breast cancer and baseline diabetes mellitus were eligible for inclusion in this analysis.
Control-matching approach
Each of the 97 adult female subjects with breast cancer and diabetes mellitus (defined as "cases") was matched with two other female subjects diagnosed with breast cancer, but without baseline diabetes mellitus (defined as "controls"). The following matching criteria were used: age at diagnosis, body mass index category, ethnicity, menopausal status and tumor stage (as per the American Joint Committee on Cancer). Some matching limitations applied [1] .
Demographic and clinical data collection
Clinical and treatment history was documented by medical chart review. Vital status was obtained from the Institute's Tumor Registry, a local database updated biannually with data obtained from the National Comprehensive Cancer Networks' Oncology Outcomes Database. Outcomes of interest were breast cancer recurrence and/or death. For additional details concerning data collection, specific definitions regarding censoring and drug use, and a comprehensive demographic report, please see the original article [1] .
Plasma specimen storage and retrieval
All the plasma specimens retrieved from long-term storage were individually aliquoted in color coded vials labeled with unique, subject specific barcodes. Overall duration of freezing time was accounted for all matched controls ensuring that the case and matched control specimens had similar overall storage conditions. Only two instances of freeze-thaw were allowed between biobank retrieval and biomarker analyses: aliquoting procedure step and actual assay.
Enzyme-linked immunosorbent assay and Luminex s assays
A total of 7 biomarkers (adiponectin, leptin, C-reactive protein, interleukine-6, interleukine-1β, interleukine-1Ra, tumor necrosis factor-α, and C-peptide) were quantified using either enzymelinked immunosorbent or Luminex s assays, as described by Wintrob et al. [1] . A quantitative colorimetric enzyme-linked immunosorbent assay was performed for detection of C-reactive protein, according to manufacturer protocol (Genway Biotek Inc., San Diego, CA). The following Luminex s biomarker panels were utilized in this study: human cytokine/chemokine panel I (MPXHCYTO-60K for interleukine-1β and interleukine-1Ra), human high sensitivity cytokine/chemokine panel (HSCYTO-60SK for interleukine-6 and tumor necrosis factorα), human cardiovascular disease panel I
